tetano
Editor, Senior Moderator
J Diabetes Investig
. 2023 Sep 11.
doi: 10.1111/jdi.14079. Online ahead of print. Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study
Tulika Chatterjee[SUP] 1 [/SUP], Naveen Ravichandran[SUP] 2 [/SUP], Narmadha Nair[SUP] 3 [/SUP], Abraham Edgar Gracia-Ramos[SUP] 4 [/SUP], Bhupen Barman[SUP] 5 [/SUP], Parikshit Sen[SUP] 6 [/SUP], Mrudula Joshi[SUP] 7 [/SUP], Sreoshy Saha[SUP] 8 [/SUP], Arvind Nune[SUP] 9 [/SUP], Arun Kumar R Pande[SUP] 10 [/SUP], Tsvetelina Velikova[SUP] 11 [/SUP], Ioannis Parodis[SUP] 12 13 [/SUP], Ai Lyn Tan[SUP] 14 15 [/SUP], Samuel Katsuyuki Shinjo[SUP] 16 [/SUP], Hiya Boro[SUP] 17 [/SUP], Vikas Agarwal[SUP] 2 [/SUP], Rohit Aggarwal[SUP] 18 [/SUP], Latika Gupta[SUP] 19 20 21 [/SUP]; COVAD Study Group
Collaborators, Affiliations
Aims/introduction: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients.
Materials and methods: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out.
Results: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients).
Conclusions: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
Keywords: COVID-19; Type 1 diabetes mellitus; Vaccine.
. 2023 Sep 11.
doi: 10.1111/jdi.14079. Online ahead of print. Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study
Tulika Chatterjee[SUP] 1 [/SUP], Naveen Ravichandran[SUP] 2 [/SUP], Narmadha Nair[SUP] 3 [/SUP], Abraham Edgar Gracia-Ramos[SUP] 4 [/SUP], Bhupen Barman[SUP] 5 [/SUP], Parikshit Sen[SUP] 6 [/SUP], Mrudula Joshi[SUP] 7 [/SUP], Sreoshy Saha[SUP] 8 [/SUP], Arvind Nune[SUP] 9 [/SUP], Arun Kumar R Pande[SUP] 10 [/SUP], Tsvetelina Velikova[SUP] 11 [/SUP], Ioannis Parodis[SUP] 12 13 [/SUP], Ai Lyn Tan[SUP] 14 15 [/SUP], Samuel Katsuyuki Shinjo[SUP] 16 [/SUP], Hiya Boro[SUP] 17 [/SUP], Vikas Agarwal[SUP] 2 [/SUP], Rohit Aggarwal[SUP] 18 [/SUP], Latika Gupta[SUP] 19 20 21 [/SUP]; COVAD Study Group
Collaborators, Affiliations
- PMID: 37697820
- DOI: 10.1111/jdi.14079
Aims/introduction: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients.
Materials and methods: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out.
Results: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients).
Conclusions: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
Keywords: COVID-19; Type 1 diabetes mellitus; Vaccine.